Eszopiclone Label Updates 2020-2026, Explained
Eszopiclone's label kept its 2019 boxed warning on complex sleep behaviors through 2026, with reinforced sex-based dosing but no urinary retention warning added.
2 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 2 of 2 clinical reviews.
Eszopiclone's label kept its 2019 boxed warning on complex sleep behaviors through 2026, with reinforced sex-based dosing but no urinary retention warning added.
A full breakdown of Lunesta (eszopiclone) FDA approval history, label changes, safety updates, and post-market surveillance data, prepared by the HealthRX.com Editorial Team.